Protocol Page


	Study ID (Protocol Number)
	AI452-005


	STUDY LOCATIONS*
	Atlanta Gastroenterology Associates Atlanta, GA 30308 Recruiting	Beth Israel Medical Center New York, NY 10003 Terminated
	Beth Israel Deaconess Medical Center Boston, MA 02215 Terminated	Duke University Medical Center Durham, NC 27710 Completed
	*Not all study site locations may be listed - please check back soon for updated information. For more information regarding other participating countries, please visit clinicaltrials.gov.

	STUDY NAME
	Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
	STUDY OVERVIEW
	At least 1 dose of pegIFNλ will be identified which is safe, well tolerated, and efficacious for the treatment of chronic hepatitis B virus infection (CHB) Amendment 7, Part B Sub Study: The primary purpose of this amendment is to obtain preliminary data on the safety of pegylated interferon Lambda (Lambda) when administered in combination with Entecavir(ETV) to patients with hepatitis E antigen-positive (HBeAg-positive) chronic hepatitis B(CHB) infection employing a sequential therapy approach

The study information provided here is a portion of what is available on ClinicalTrials.gov. Please visit ClinicalTrials.gov for complete information about this and other clinical studies.